VEGFR2-Mediated Vascular Dilation as a Mechanism of VEGF-Induced Anemia and Bone Marrow Cell Mobilization
2014 (English)In: Cell reports, ISSN 2211-1247, Vol. 9, no 2, 569-580 p.Article in journal (Refereed) Published
Molecular mechanisms underlying tumor VEGF-induced host anemia and bone marrow cell (BMC) mobilization remain unknown. Here, we report that tumor VEGF markedly induced sinusoidal vasculature dilation in bone marrow (BM) and BMC mobilization to tumors and peripheral tissues in mouse and human tumor models. Unexpectedly, anti-VEGFR2, but not anti-VEGFR1, treatment completely blocked VEGF-induced anemia and BMC mobilization. Genetic deletion of Vegfr2 in endothelial cells markedly ablated VEGF-stimulated BMC mobilization. Conversely, deletion of the tyrosine kinase domain from Vegfr1 gene (Vegfr1(TK-/-)) did not affect VEGF-induced BMC mobilization. Analysis of VEGFR1(+)/VEGFR2(+) populations in peripheral blood and BM showed no significant ratio difference between VEGF-and control tumor-bearing animals. These findings demonstrate that vascular dilation through the VEGFR2 signaling is the mechanism underlying VEGF-induced BM mobilization and anemia. Thus, our data provide mechanistic insights on VEGF-induced BMC mobilization in tumors and have therapeutic implications by targeting VEGFR2 for cancer therapy.
Place, publisher, year, edition, pages
Elsevier (Cell Press): OAJ / Elsevier , 2014. Vol. 9, no 2, 569-580 p.
IdentifiersURN: urn:nbn:se:liu:diva-112832DOI: 10.1016/j.celrep.2014.09.003ISI: 000344469100017PubMedID: 25310988OAI: oai:DiVA.org:liu-112832DiVA: diva2:776821
Funding Agencies|Swedish Research Council; Swedish Cancer Foundation; Karolinska Institute Foundation; Karolinska Institute distinguished professor award; Torsten Soderbergs Foundation; Novo Nordisk Foundation; European Research Council advanced grant ANGIOFAT 2015-01-082014-12-172015-01-13